Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why the COVID-19 vaccine market won’t be ‘winner take all’

By Brian Buntz | November 16, 2020

COVID-19 virus

[Image courtesy of Wikipedia]

There are a dozen Phase 3 COVID-19 vaccine candidates with more than 50 in either Phase 1 or Phase 2 trials. But the fact that Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have vaccine candidates with efficacy greater than 90% could ultimately narrow the playing field.

“Efficacy matters, but I don’t think [Pfizer’s and Moderna’s efficacy rate of] greater than 90% shuts others down in the near term,” said Navin Jacob, a senior equity research analyst specializing in biotech and pharmaceuticals at UBS.

Still, the Pfizer and Moderna vaccines’ performance is far greater than the FDA’s COVID-19 vaccine requirement to prevent infections or decrease its severity in at least 50% of people.

The solid performance of vaccine candidates from Pfizer and Moderna could be bad news for vaccines that fail to offer similar performance. The prospects of less-effective vaccines will likely diminish, “possibly leading the field to be winnowed sooner than later,” according to Michael Breen, director of infectious diseases and ophthalmology at GlobalData.

The considerable demand for vaccines will ensure that COVID-19 vaccines are not a winner-take-all market, Jacob said. There is “not enough capacity to feed world demand,” he said.

The durability of vaccines is another wildcard. “Most companies and experts are saying one to two years of durability, which means we will need to boost again in a couple of years, which means even more demand,” Jacob added.

Another factor that could drive a heterogeneous vaccine market is regulatory agencies’ desire to have an arsenal of vaccines and medications available to battle the epidemic. “No regulatory agency wants to put the entire country’s health on the back of one or maybe even two companies/vaccines,” Jacob said. “They want to be able to spread the risk in case something happens to any one company or vaccine.”

Differences in safety profiles between vaccines could lead to certain vaccines being a better fit for a given patient population. Currently, however, there is a lack of long-term safety data regarding any COVID-19 vaccine.

Ultimately, the strong results from Pfizer and Moderna are potentially bad news for vaccine candidates that are close to FDA’s 50% efficacy requirement. “I don’t think you can get away with 60% efficacy either,” Jacob said. “Perhaps 75–80% is good enough if you have something differentiated.”

Other than efficacy, different potential ways vaccines could differentiate themselves include ease of storage requirements. A room-temperature stable vaccine would have a considerable advantage over one that must be stored at –70° C, such as Pfizer’s.

An oral delivery mechanism would be another advantage. Harvard University researchers, for instance, have developed a potential technique to deliver vaccines through oral administration.

While Jacob sees room for differentiation, “I don’t think you can have a vaccine that has much difference in severe COVID case reduction,” he said. “That has to be much more similar to whatever MRNA and PFE/BNTX show when we see final data.”

 


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Moderna, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE